Acute myeloid leukaemia (AML)

In 1930, it was discovered that children with Down syndrome are at a greater risk of developing certain types of leukaemia, but much of our understanding of this link remains a mystery.

Cancer Research UK’s spin-out, GammaDelta Therapeutics, has been given approval to trial its unique T-cell therapy in the US.  

Scientists are developing a new drug for treating acute myeloid leukaemia (AML), a type of blood cancer that affects around 3,100 people in the UK each year. 

New research shows a type of aggressive blood cancer could be made more sensitive to chemotherapy using an antibiotic currently available to treat diarrhoea.

The targeted drug gilteritinib is now recommended for some adults with acute myeloid leukaemia (AML) on the NHS in England.  

Leukaemia and head and neck cancer drugs have not been recommended for NHS use in England.

Researchers studying the genetic make-up of an aggressive blood cancer, AML, have discovered that it exists in at least 11 different forms.

Researchers showed that the presence of leukaemia cells after initial chemotherapy could predict how well a patient subsequently fared.

UK scientists have found that a pair of genes inside cells could play a major role in how a serious form of leukaemia develops.

Scientists have identified a gene – FOXC1 – that, if switched on, causes more aggressive cancer in a fifth of acute myeloid leukaemia (AML) patients